Ellevest Inc’s Cyclerion Therapeutics CYCN Stock Holding History

Ellevest Inc’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1	Closed	–	–	1165
2020 Q1	$0	Buy	+1	New	+$71	﹤0.01%	1122

Other funds holding CYCN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ellevest Inc's CYCN Position: Q2 2020 in Review

Ellevest Inc sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 1 share.

Ellevest Inc first reported a position in CYCN in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

Ellevest Inc reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
Ellevest Inc sold 1 Cyclerion Therapeutics share in Q2 2020.
Ellevest Inc first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 1 quarter.
Ellevest Inc's Cyclerion Therapeutics position peaked at $0 in Q1 2020.
74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Ellevest Inc's 13F filing for Q2 2020, filed 6 Jul 2020.